1Department of Pharmaceutical Technology, School of Pharmacy, Université Catholique de Louvain, 1200 Brussels, Belgium; and 2Division of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138
Submitted 29 July 2003 ; accepted in final form 22 December 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() |
---|
pulmonary drug delivery; protein degradation; absorption enhancement
The exact nature of protein absorption into the bloodstream and elimination from the lungs is unclear, although it appears certain that most protein absorption occurs in the large and highly vascularized alveolar region, with the alveolar epithelium playing a key role in regulating protein passage into the bloodstream (8, 25, 30, 32). It has long been assumed that the primary obstacles to an efficient absorption of inhaled proteins reside in the barrier property of the alveolar epithelium and local proteases (8, 25, 30, 32). Therefore, strategies to increase systemic absorption of macromolecules from the lungs over the last decade have primarily involved membrane permeation enhancers (such as bile salts) that act to better permeabilize the lung's epithelium or protease inhibitors that neutralize local enzyme activities (14, 15, 18).
We demonstrate that alveolar macrophages (AM) comprise a major "barrier" to the transport of macromolecules from the lungs into the bloodstream, particularly for moderate-sized to large proteins. Using intratracheal instillation of liposomeencapsulated dichloromethylene diphosphonate (Cl2MDP), we depleted rat lungs of AM and thereby assessed their role in the pulmonary fate of proteins in vivo. Severalfold enhancement in systemic absorption of immunoglobulins and human chorionic gonadotropin (hCG) from the lungs followed the elimination of AM. Our studies suggest a novel means for enhancing the efficiency of protein absorption from the lungs, i.e., lowering AM uptake of macromolecules by chemical or physical means. For certain proteins, such as immunoglobulins, diminishing the total delivered dose also provides a simple and efficient physical method to diminish degradation and dramatically favor systemic absorption of the macromolecule from the lungs.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() |
---|
Animals. Twelve-week-old male Wistar rats were supplied by Elevage Janvier (Le Genest St Isle, France) and used within 3 wk of delivery for confocal laser scanning microscopy studies and within 1 wk for pharmacokinetic studies. Animals had free access to tap water and laboratory diet (pelleted commercial standard diet no. A04; Usin Alimentation Rationnelle, Epinay-sur-Orge, France) and were kept on a 12-h day-night cycle until they were used. Rats were anesthetized with ketamine/xylazine (90/10 mg/kg) intraperitoneal injection before intratracheal or intravenous (IV) injections as well as before lung preparation for analysis by confocal laser scanning microscopy. Slighter anesthesia was given before orbital bleeding. All experimental protocols in rats were approved by the Institutional Animal Care and Use Committee of the Université catholique de Louvain.
Confocal laser scanning microscopy. Rat IgG1 anti-dinitrophenyl hapten and hCG were custom labeled with FITC (19). FITC-IgG, FITC-hCG, and FITC-insulin were localized by confocal laser scanning microscopy in the pulmonary tissue after intratracheal instillation in rats, as previously described (19). Briefly, 500 µg of FITC-IgG, 100 µg of FITC-hCG, or 40 µg of FITC-insulin (dissolved in 100 µl of NaCl 0.9%) were instilled in the rat lungs using a Microsprayer device (PennCentury, Philadelphia, PA) inserted in the trachea via the mouth. Within 1 min and at intervals up to 4 days after intratracheal delivery, the lungs were lavaged and fixed by vascular perfusion of PBS (pH 7.4) containing 0.1% sulforhodamine for 5 min and then a fixative solution (0.6% formaldhehyde, 0.9% glutaraldehyde, 75 mM sodium cacodylate, and 0.1% sulforhodamine, adjusted to pH 7.4) for an additional 5 min. The thoracic cavity was opened, and the lungs were removed for analysis by confocal laser scanning microscopy. The total time for intratracheal delivery and lung preparation for microscopy was 15 min. Each experimental condition was repeated at least three times.
Slices (± 2 mm) of the lobes and trachea were placed directly in a sample holder and covered with a coverslip glass. The confocal microscope was a Bio-Rad MRC 1024 confocal unit equipped with an argon-krypton laser and mounted on a Zeiss Axiovert 135M inverted microscope. Laser excitation wavelengths of 488 and 568 nm were used individually to scan lung tissue, and fluorescent emissions from FITC (emission = 515545 nm) and sulforhodamine (emission
= 589621 nm) were collected using separate channels. Images were acquired with a Zeiss Plan-Neofluor x40 oil immersion and x10 lenses. Grayscale images (obtained from each scan) were pseudocoloredgreen(FITC-IgG,FITC-hCG,orFITC-insulin)andred(sulforhodamine) and then overlaid (Zeiss LSM confocal software) to form a multicolored image.
The uptake of FITC-IgG by AM was further visualized by analyzing AM collected by bronchoalveolar lavage (BAL). The rats were killed with an overdose of pentobarbital 2 h after FITC-IgG delivery. The airways and lungs were washed with Hanks' balanced salt solution without Ca2+, Mg2+, and phenol red to minimize cell clumping. The BAL was obtained by slowly injecting 10 ml of Hanks' balanced salt solution into the trachea, waiting for 30 s, and then withdrawing the liquid from the lungs. The lavage procedure was repeated with four additional 10-ml aliquots until a total volume of 50 ml was injected. The BAL was centrifuged at 700 g and 4°C for 10 min. The supernatant was removed, and the cells were resuspended in 1 ml of Hanks' balanced salt solution. A few droplets of the cell suspension were placed directly in a sample holder and covered with a coverslip glass for analysis by confocal laser scanning microscopy.
To assess the autofluorescence properties of the pulmonary tissue, samples were examined with the confocal microscope in the absence of administration of fluorescent markers. The autofluorescence of the rat lung in the green channel was found to be very low with the confocal settings used in this study, except in peripheral regions where fiber networks and cells exhibited high autofluorescence (data not shown). To avoid these areas of high-fluorescence background, confocal images were collected only in regions at least 10 µm below lung surface (19).
Preparation of Cl2MDP and PBS liposomes. Eighty-six milligrams of lecithin and 10 mg of cholesterol were dissolved in 10 ml of chloroform. A lipid film was produced by low-vacuum rotary evaporation, and the film was dispersed by gentle rotation in 10 ml of PBS or 10 ml of Cl2MDP solution (2.5 g/10 ml of sterile water). After the film was completely removed, the suspension was kept for 30 min at room temperature under nitrogen atmosphere, and the suspension was sonicated for 2 min at a power of 60 W (Sympatec, Clausthal-Zellerfelg, Germany). Free Cl2MDP was removed by dilution of the suspension in 100 ml of PBS and centrifugation at 10,000 rpm for 30 min. The liposome pellet was resuspended in 1.5 ml of PBS. The suspension of Cl2MDP or PBS liposomes was stored under nitrogen atmosphere at 4°C for a maximum of 1 wk (29).
Depletion or IT instillation of AM. Seven hundred and fifty microliters of PBS or Cl2MDP liposome suspension or of 0.9% NaCl were instilled in the trachea of rats using a syringe inserted via the mouth. AM depletion resulting from Cl2MDP was assessed by analyzing cellular components in BAL before and 1, 2.5, and 5 days after liposome or saline delivery. The total number of cells was determined by mixing with Turch liquid and counting with a hemacytometer. AM were differentiated from neutrophils on cytocentrifuge preparations fixed in methanol and stained with Diff-Quik (300 cells/rat; Dade Berhing, Düdingen, Switzerland). Lung histology was used to assess the integrity of the airway and alveolar epithelia after instillation of PBS or Cl2MDP liposomes. Rats were killed 24 h after treatment of the lungs with liposomes. The lobes and trachea were removed and placed in a 4% formol solution. Paraffin-embedded histological sections were stained with hematoxylin/eosin and examined by light microscopy.
An increase in the number of AM present locally in the lungs was achieved by instilling additional AM into the lungs of intact rats. AM were collected by BAL, the suspensions of AM from several rats were pooled, and five million cells (a BAL from 1 rat yields an average of 2.5 million AM) suspended in 200 µl of Hanks' balanced salt solution were intratracheally instilled into the lungs of each intact animal. It is noteworthy that five million AM represent only 20% of the total AM population in rats (28).
Pharmacokinetic studies. Rats (413 ± 21 g) were intratracheally instilled with liposomes or additional AM 1 day or 1 h, respectively, before pulmonary administration of the therapeutic protein or peptide, or remained untreated. The rats received 5, 50, or 500 µg of IgG, 100 µg (840 IU) of hCG, or 40 µg (465 mIU) of human insulin by intratracheal instillation (100 µl of 0.9% NaCl solution) or 5 or 50 µg of IgG, 10 µg of hCG, or 10 µg of human insulin by IV injection (500 µl of 0.9% NaCl solution).
The three doses of IgG delivered to the lungs were chosen according to the quantities of total IgG naturally present in the lungs of untreated rats (52 ± 13 µg, as measured in BAL). We hypothesized that a low (5 µg), an equivalent (50 µg), and a high (500 µg) dose comparative to local levels would allow us to observe the activation of increased IgG clearance once levels exceeded normality.
Serum was collected by orbital bleeding at intervals up to 42 days, 3 days, or 6 h after administration of IgG, hCG, or insulin, respectively. IgG concentrations in serum were measured by enzyme-linked immunosorbent assay. Plates (Nunc-Immuno Plate Maxisorp Surface, GIBCO-BRL Life Technologies) were coated with dinitrophenyl human albumin, incubated with dilutions of sera, and developed with horseradish peroxidase-conjugated anti-rat IgG Fc region. Serum levels of hCG and insulin were measured by enzyme immunoassay (Biosource, Nivelles, Belgium) and immunoradiometric assay (Biosource), respectively.
The areas under the serum concentration-time curves (AUC) were calculated using the linear trapezoidal rule, and the absolute bioavailability of intratracheal instillation was calculated by comparison to IV injection as
![]() | (1) |
Statistics. The data were validated by the Dixon test. Results are expressed as means ± SE. ANOVA and Tukey's test were performed to demonstrate statistical differences (P < 0.05) using the software Sigma-Stat for Windows (SPSS, San Rafael, CA).
![]() |
RESULTS AND DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() |
---|
|
Effect of AM uptake on systemic bioavailability. Whereas previous studies either did not assess (10, 19, 31) or concluded negligible (3) the effect of AM protein uptake on systemic bioavailability, we hypothesized that an important local elimination mechanism of macromolecules involved clearance by AM and hence that its inhibition could lead to significant enhancement of pulmonary bioavailability. To verify this, we eliminated AM using liposomes containing Cl2MDP and compared serum IgG levels after pulmonary administration of IgG to AM-depleted rats and control rats. Selective depletion of splenic, liver, or AM by Cl2MDP liposomes has largely been used to study macrophage function in physiology, pathology, or immunity (2, 26). In our experiments, a single IT dose of Cl2MDP liposomes in rats decreased AM number in BAL from 2.3 ± 0.4 million to 0.5 ± 0.1 million at day 1 after delivery (Fig. 2A). AM number remained low for the next 36 h, and repopulation of the lungs with AM was observed at day 5. In contrast, animals treated with liposomes prepared with PBS and no Cl2MDP showed normal AM population throughout the period examined (Fig. 2A). IT instillation of Cl2MDP or PBS liposomes or of simply 0.9% NaCl caused a slight and similar neutrophil influx in the air spaces (P > 0.10; Fig. 2B) and no structural alterations to airway or alveolar epithelia (Fig. 3), as previously reported (2, 13). Regions of atelectasis were apparent in histological lung sections after administration of liposomes (Fig. 3, B and C). One day after liposome treatment, rats were intratracheally instilled with 500 µg of IgG, and the subsequent absorption of IgG in blood that occurred is shown in Fig. 4. A substantial rise in serum IgG levels resulted from the depletion of AM; the pulmonary bioavailability relative to IV injection increased from 4.7% in untreated rats (or 4.5% in PBS liposome-treated rats) to 10.5% in Cl2MDP liposometreated rats (Fig. 4; P < 0.05). Conversely, when we instilled additional AM into rat lungs, we observed a decrease in pulmonary bioavailability of IgG to 2.6% (Fig. 4; P < 0.05). In all cases, serum IgG levels were affected by AM number within the first hours of the absorption phase (Fig. 4), indicating that AM clearance was rapidly effective. The responsiveness of IgG absorption from the lungs on AM number demonstrates that AM present a significant hindrance to IgG transport from airway lumen to the bloodstream, contrary to previous arguments for a lesser role (8, 10, 25, 32).
|
|
|
|
|
|
The uptake of fluid by endocytosis is a natural characteristic of professional phagocytes (22). Because uptake is low but uninterrupted, significant internalization of tracers needs periods of several minutes to hours (17). Given these features, we expected AM clearance to be a most significant barrier to pulmonary absorption of macromolecules with hours of persistence in the airway lumen and to have no impact on pulmonary absorption of peptides, which are cleared within minutes.
To verify this assumption, we assessed the impact of AM on pulmonary absorption of the peptide insulin. Confocal imaging showed that FITC-insulin was eliminated rapidly from the lungs, with an apparent binding to tissue fibers but no uptake by AM (Fig. 5, B and C). Transport of instilled insulin to the bloodstream increased after lung treatment with PBS liposomes (P < 0.05) but, in contrast to IgG and hCG, no additional increase was associated with AM depletion due to Cl2MDP (Fig. 7; P > 0.10). The absolute bioavailability of pulmonary insulin was 3.1, 13.3, and 8.7% in untreated, PBS liposomes and Cl2MDP liposome-treated rats, respectively (P < 0.05, PBS and Cl2MDP liposomes vs. untreated rats; P > 0.10, PBS vs. Cl2MDP liposomes). This shows that Cl2MDP liposomes did not cause additional permeability change to the epithelium compared with PBS liposomes and that AM clearance is a slow process that does not impact on pulmonary absorption of peptides.
|
Strategies for enhancing pulmonary bioavailability. Our studies suggest that pinocytic uptake by AM represents a degradation pathway for inhaled proteins, which competes with absorption of proteins across lung epithelia and thereby lowers pulmonary bioavailability to the degree that the rate of AM uptake and degradation is near to or greater than the rate of transport from the lung lumen into the bloodstream. On the basis of this conclusion, we hypothesized two strategies to increase pulmonary bioavailability. A first conventional strategy is suggested by the enhancement in pulmonary absorption of hCG and insulin that followed pretreatment of the lungs with PBS liposomes (Figs. 6 and 7) and consists of increasing the rate of protein transport across the alveolar epithelium by chemical means (14, 15, 18). In this regard, the coadministration of peptide drugs and of dipalmitoylphosphatidylcholine, the most abundant phospholipid component of pulmonary surfactant, has been reported, interestingly, to accelerate and increase drug absorption from the lungs in rats, whatever the mode of delivery, instillation of a physical dispersion in saline or inhalation of a dry powder aerosol (6, 21).
A second strategy, implied by our experiments involving Cl2MDP liposomes, requires lowering the rate of AM uptake to increase pulmonary bioavailability. For proteins such as IgG, for which primary cultured rat epithelial cell monolayer studies have shown protein absorption to be a saturable process (12, 20) [pinocytosis by macrophages is in contrast a sustained phenomenon (22)], decreasing the doses of the protein delivered to the lungs might favor absorption to the systemic circulation relative to local degradation. To assess this hypothesis, we delivered to rat lungs IgG doses of 500, 50, and 5 µg and observed less than a proportional decrease in serum IgG levels (Fig. 8A), whereas decreasing the IgG dose injected intravenously from 50 to 5 µg did cause a proportional decrease in serum IgG levels (Fig. 8B). This translates into an increase in absolute IgG bioavailability from 4.7 to 10.9 (P < 0.05) to 38.4% (P < 0.05) for the 500-, 50-, and 5-µg doses instilled, respectively. The absolute bioavailability of 1.5% previously reported in rats at a dose of 5 mg is consistent with this trend (9).
Chemical or physical alternatives of minimizing AM clearance relative to absorption include the inhibition of endocytosis using physiological modulators (4, 17), the coadministration of ligands competing with proteins for binding on macrophage plasma membranes (17), and the preparation of large porous particles that could protect the drug from local pinocytic and phagocytic degradation and release it at a rate slightly slower than the rate of absorption (7). These approaches could be appropriately applied to macromolecules due to their long residence times in the alveoli, but could also be extended to sustained-release formulations of molecules that lack physical protection against AM clearance. Systemic drug absorption after inhalation could be improved, but therapeutics or prophylactic drugs delivered to the lungs for a local action could improve in efficacy from these strategies as well.
![]() |
ACKNOWLEDGMENTS |
---|
R. Vanbever is a Chercheur Qualifié of the Fonds National de la Recherche Scientifique (Brussels, Belgium).
GRANTS
This work was funded in part by Advanced Inhalation Research (Alkermes; Cambridge, MA).
![]() |
FOOTNOTES |
---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() |
---|
|
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Visit Other APS Journals Online |